1. How many patients have been treated with the following drugs (for any disease) in the past 6 months:
a. Aubagio (teriflunomide)
b. Avonex (interferon beta-1a)
c. Betaferon (interferon beta-1b)
d. Brabio (glatiramer acetate)
e. Copaxone (glatiramer acetate)
f. Extavia (beta interferon-1b)
g. Fampyra (fampridine)
h. Gilenya (fingolimod)
i. Lemtrada (alemtuzumab)
j. Mavenclad (cladribine)
k. Mayzent (siponimod)
l. Ocrevus (ocrelizumab)
m. Plegridy (peginterferon beta-1a)
n. Rebif (beta interferon-1a)
o. Tecfidera (dimethyl fumarate)
p. Tysabri (natalizumab)
q. Zeposia (ozanimod)
Q2. How many patients have been treated with the following drugs in the past 4 months:
a. Aimovig (erenumab) – any disease
b. Ajovy (fremanezumab) – any disease
c. Emgality (galcanezumab) – any disease
d. Botulinum Toxin (i.e. Botox, Dysport, Xeomin) – for migraine ONLY
Q3. Does the trust either commission or fund Botulinum Toxin treatment and/or anti-CGRP monoclonal antibody treatments (Ajovy, Aimovig, Emgality) for migraine (Y/N)?
Q4. How many patients have been treated in the past 4 months for the following conditions:
a. Chronic migraine (15+ headache days per month)
b. Episodic migraine (4-14 headache days per month)
c. Relapsing remitting multiple sclerosis (RRMS)
d. Primary progressive multiple sclerosis (PPMS)
e. Secondary progressive multiple sclerosis (SPMS)

Download response Treatment of neurology patients. 011221.docx